Point72 Asset Management L.P. 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-02-14 06:11 am Sale | 2023-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | Point72 Asset Management L.P. | 209,971 0.200% | -4,323,785![]() (-95.37%) | Filing |
2023-04-05 4:23 pm Purchase | 2023-04-04 | 13G | Esperion Therapeutics, Inc. ESPR | Point72 Asset Management L.P. | 4,533,756 5.000% | 2,095,618![]() (+85.95%) | Filing |
2023-02-14 4:14 pm Sale | 2022-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | Point72 Asset Management L.P. | 2,438,138 4.200% | -1,032,140![]() (-29.74%) | Filing |
2022-08-23 4:59 pm Purchase | 2022-08-22 | 13G | Esperion Therapeutics, Inc. ESPR | Point72 Asset Management L.P. | 3,470,278 5.200% | 3,470,278![]() (New Position) | Filing |